We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Amazon, Berkshire Hathaway, Thermo Fisher, Square and Public Service
Read MoreHide Full Article
For Immediate Release
Chicago, IL –March 8, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon (AMZN - Free Report) , Berkshire Hathaway (BRK.B - Free Report) ,Thermo Fisher (TMO - Free Report) , Square (SQ - Free Report) and Public Service Enterprise Group (PEG - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Amazon, Berkshire and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, Berkshire Hathaway and Thermo Fisher. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Amazon’s shares have outperformed the broader market in the past year (the stock is up +7.5% vs. the +1.4% increase for the S&P 500 as a whole). The Zacks analyst thinks Amazon continues to ride on its ecommerce dominance. Its aggressive retail strategies, distribution strength and robust Prime remain the key catalysts.
Rapid adoption of Prime owing to its customer benefits and strengthening grocery services is driving its top-line growth. Further, the company’s growing brick and mortar presence is a tailwind. Additionally, Amazon’s continued momentum in AWS remains a major positive.
Increasing AWS regions and its growing adoption will continue to aid Amazon’s cloud momentum. Also, improving Alexa features and the growing number of device compatible with it are expected to aid the company’s momentum in the virtual assistant market.
However, first-quarter 2019 revenue guidance remains disappointing. Rising cloud competition from the likes of Microsoft Azure and Google cloud is a significant headwind. Also, heavy investment in fulfillment centers is a concern.
Shares of Strong Buy-rankedBerkshire Hathaway’s shares have outperformed the Zacks Insurance - Property and Casualty industry over the past year (-2.3% vs. -3.3%). Berkshire reported fourth quarter earnings of $5.7 billion, up 71.4% year over year on solid results across all segments. The Zacks analyst thinks the company is poised for growth over the longer-term banking on its sturdy insurance business. Its property and casualty insurance business generate maximum return on equity.
The company’s inorganic growth story remains impressive with strategic acquisitions. A strong cash position allows it to make earnings-accretive bolt-on buyouts. Demand for utilities is expected to rise in the future and drive earnings growth. Continued insurance business growth also fuels increase in float. A sturdy capital level provides further impetus.
However, its exposure to catastrophe loss remains a worry. Huge capital expenses due to railroad operations pose concerns. Capital expenditure is estimated to be $10.5 billion in 2019.
Thermo Fisher’s shares have outperformed the Zacks Medical Instruments industry in the past three months (+6% vs. +4.4%). Thermo Fisher ended the fourth quarter 2018 on a promising note, showing strength in all end markets categorized either by customer type or geography.
The company particularly registered solid international performance with strong growth in Asia-Pacific including China. Also, a series of product launches with progress in precision medicine initiatives aided its performance. The Zacks analyst is currently looking forward to the company’s recent purchases of Advanced Bioprocessing business from BD and its initiative to buy Gatan to boost electron microscopy suite.
Even after considering the impact of the company’s impending divestiture of its Anatomical Pathology business, the 2019 guidance looks pretty encouraging. On the flip side, Thermo Fisher’s business segments are getting impacted by unfavorable business mix. Also, competitive headwinds and escalating costs pose a threat.
Other noteworthy reports we are featuring today include Square and Public Service Enterprise Group.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Amazon, Berkshire Hathaway, Thermo Fisher, Square and Public Service
For Immediate Release
Chicago, IL –March 8, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon (AMZN - Free Report) , Berkshire Hathaway (BRK.B - Free Report) ,Thermo Fisher (TMO - Free Report) , Square (SQ - Free Report) and Public Service Enterprise Group (PEG - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Amazon, Berkshire and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, Berkshire Hathaway and Thermo Fisher. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Amazon’s shares have outperformed the broader market in the past year (the stock is up +7.5% vs. the +1.4% increase for the S&P 500 as a whole). The Zacks analyst thinks Amazon continues to ride on its ecommerce dominance. Its aggressive retail strategies, distribution strength and robust Prime remain the key catalysts.
Rapid adoption of Prime owing to its customer benefits and strengthening grocery services is driving its top-line growth. Further, the company’s growing brick and mortar presence is a tailwind. Additionally, Amazon’s continued momentum in AWS remains a major positive.
Increasing AWS regions and its growing adoption will continue to aid Amazon’s cloud momentum. Also, improving Alexa features and the growing number of device compatible with it are expected to aid the company’s momentum in the virtual assistant market.
However, first-quarter 2019 revenue guidance remains disappointing. Rising cloud competition from the likes of Microsoft Azure and Google cloud is a significant headwind. Also, heavy investment in fulfillment centers is a concern.
(You can read the full research report on Amazon here >>>).
Shares of Strong Buy-rankedBerkshire Hathaway’s shares have outperformed the Zacks Insurance - Property and Casualty industry over the past year (-2.3% vs. -3.3%). Berkshire reported fourth quarter earnings of $5.7 billion, up 71.4% year over year on solid results across all segments. The Zacks analyst thinks the company is poised for growth over the longer-term banking on its sturdy insurance business. Its property and casualty insurance business generate maximum return on equity.
The company’s inorganic growth story remains impressive with strategic acquisitions. A strong cash position allows it to make earnings-accretive bolt-on buyouts. Demand for utilities is expected to rise in the future and drive earnings growth. Continued insurance business growth also fuels increase in float. A sturdy capital level provides further impetus.
However, its exposure to catastrophe loss remains a worry. Huge capital expenses due to railroad operations pose concerns. Capital expenditure is estimated to be $10.5 billion in 2019.
(You can read the full research report on Berkshire Hathaway here >>>).
Thermo Fisher’s shares have outperformed the Zacks Medical Instruments industry in the past three months (+6% vs. +4.4%). Thermo Fisher ended the fourth quarter 2018 on a promising note, showing strength in all end markets categorized either by customer type or geography.
The company particularly registered solid international performance with strong growth in Asia-Pacific including China. Also, a series of product launches with progress in precision medicine initiatives aided its performance. The Zacks analyst is currently looking forward to the company’s recent purchases of Advanced Bioprocessing business from BD and its initiative to buy Gatan to boost electron microscopy suite.
Even after considering the impact of the company’s impending divestiture of its Anatomical Pathology business, the 2019 guidance looks pretty encouraging. On the flip side, Thermo Fisher’s business segments are getting impacted by unfavorable business mix. Also, competitive headwinds and escalating costs pose a threat.
(You can read the full research report on Thermo Fisher here >>>).
Other noteworthy reports we are featuring today include Square and Public Service Enterprise Group.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.